🔎 Trials Near Me

Akèy › Kansè Ezofajyen › Tennessee › Nashville

Etid klinik pou Kansè Ezofajyen nan Nashville, TN

19 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology PLLC, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Ap rekriteFaz 2
  • SCRI Oncology Partners, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon Research Institute - Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon Research Institute- Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07519655

DESTINY-PANTUMOUR04

Ap rekriteEtid obsèvasyon
  • Research Site, Nashville
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Ap rekriteFaz 1/2
  • Vanderbilt University Medical Center, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Ap rekriteFaz 1/2
  • Sarah Cannon Research Institue, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon - Tennessee Oncology, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon Research Institute, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Ap rekriteFaz 2
  • SCRI Oncology Partners, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Ap rekriteFaz 1
  • US Oncology Research LLC, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Sarah Cannon Research Institute, Nashville
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

Ap rekriteEtid obsèvasyon
  • Veterans Affairs Medical Center - Nashville, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT00899626

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Vanderbilt-Ingram Cancer Center, Nashville
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

Ap rekriteFaz 1
  • Sarah Cannon Research Institute (SCRI), Nashville
Laj 18 ak plis · Tout sèks · Mizajou Jan 12, 2026 · NCT07181473

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Nashville
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Etid Kansè Ezofajyen nan lòt vil

Lòt etid nan Nashville

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.